WASHINGTON -- The Food and Drug Administration said it is “increasingly likely” that Pfizer Inc.'s smoking-cessation drug Chantix may be tied to serious psychiatric symptoms. The FDA’s comment is part of a public health advisory issued Friday.
WASHINGTON -- The Food and Drug Administration said it is “increasingly likely” that Pfizer Inc.'s smoking-cessation drug Chantix may be tied to serious psychiatric symptoms. The FDA’s comment is part of a public health advisory issued Friday.
